








Figure S1. Flow diagram for selecting oesophageal adenocarcinoma cases. All cases originated from the OCCAMS database. Abbreviations: OCCAMS, Oesophageal Cancer Classification and Molecular Stratification; BE, Barrett’s esophagus.






A**B****C****D**

275 BE unknown EAC samples from 275 patients




EAC +ve
Stage I




EAC +ve

Stage II




EAC +ve

Stage III




Stage IV




EAC +ve

Stage IV




EAC -ve

Stage I



Stage III



EAC -ve

Stage IV




Table S1. Baseline demographics of esophageal adenocarcinoma (EAC) cases overall and according to tumor phenotype.

Characteristic	BE+ve EAC (n=1,235)	BE-ve EAC (n=880)	BE(?) EAC (n=985)	Overall (n=3,100)
Age at diagnosis; years				
Mean [SD]	66.7 [9.2]	65.5 [9.8]	65.3 [10.2]	65.9 [9.7]
Median [Q1, Q3]	67.5 [61.4, 73.5]	66.7 [59.0, 72.6]	66.7 [58.6, 72.9]	67.0 [59.8, 73.0] -
Age groups at diagnosis, n (%)				
< 50 years old	67 (5.4)	59 (6.7)	75 (7.6)	201 (6.5)
50 - 59 years old	193 (15.6)	184 (20.9)	213 (21.6)	590 (19.0)
60 - 69 years old	497 (40.2)	317 (36.0)	333 (33.8)	1147 (37.0)
70+ years old	478 (38.7)	320 (36.4)	364 (37.0)	1162 (37.5)
Sex, n (%)				
Female	163 (13.2)	158 (18.0)	161 (16.3)	482 (15.5)
Male	1072 (86.8)	722 (82.0)	824 (83.7)	2618 (84.5)
Ethnicity, n (%)				
Other	20 (1.71)	11 (1.32)	23 (2.42)	54 (1.83)
White Caucasian	1152 (98.3)	822 (98.7)	928 (97.6)	2902 (98.2)
Missing	63 (5.1)	47 (5.3)	34 (3.5)	144 (4.6)

Table S2. Sensitivity analyses of the adjusted association of baseline characteristics with risk of BE+ve EAC compared to BE+ve EAC cases using multiple imputation, complete case analysis and exclusion of EAC cases with a history of undergoing BE surveillance.

Characteristic	Multiple imputation	Complete case analysis			Excluding BE surveillance EAC cases (n=214)		
	Fully adjusted model ^a OR (95% CI, p)	BE+ve EAC n (%)	BE-ve EAC n (%)	Fully adjusted model ^a OR (95% CI, p)	BE+ve EAC n (%)	BE-ve EAC n (%)	Fully adjusted model ^a OR (95% CI, p)
Age group at diagnosis							
< 50	1.00 (Referent)	28 (6.2)	24 (7.5)	1.00 (Referent)	56 (5.1)	59 (6.9)	1.00 (Referent)
50 - 59	1.13 (0.74-1.73, p=0.577)	65 (14.4)	58 (18.1)	1.20 (0.61-2.39, p=0.598)	174 (16.0)	179 (20.8)	1.02 (0.66-1.58, p=0.917)
60 - 69	0.72 (0.48-1.07, p=0.107)	168 (37.2)	130 (40.5)	1.02 (0.55-1.92, p=0.946)	437 (40.1)	309 (36.0)	0.68 (0.45-1.02, p=0.064)
70+	0.70 (0.47-1.04, p=0.077)	191 (42.3)	109 (34.0)	0.69 (0.37-1.31, p=0.253)	423 (38.8)	312 (36.3)	0.68 (0.45-1.02, p=0.064)
Sex							
Female	1.00 (Referent)	56 (12.4)	58 (18.1)	1.00 (Referent)	144 (13.2)	151 (17.6)	1.00 (Referent)
Male	0.67 (0.52-0.87, p=0.002)	396 (87.6)	263 (81.9)	0.61 (0.40-0.93, p=0.022)	946 (86.8)	708 (82.4)	0.68 (0.53-0.88, p=0.004)
BMI group at baseline							
Normal	1.00 (Referent)	126 (27.9)	99 (30.8)	1.00 (Referent)	245 (22.5)	248 (28.9)	1.00 (Referent)
Overweight	0.89 (0.70-1.13, p=0.359)	191 (42.3)	143 (44.5)	1.10 (0.77-1.57, p=0.612)	362 (33.2)	307 (35.7)	0.91 (0.72-1.16, p=0.445)
Obese	0.57 (0.44-0.75, p<0.001)	135 (29.9)	79 (24.6)	0.78 (0.52-1.16, p=0.222)	258 (23.7)	154 (17.9)	0.63 (0.48-0.83, p=0.001)
Missing	-	-	-	-	225 (20.6)	150 (17.5)	0.93 (0.67-1.29, p=0.662)
Cigarette smoking status							
Never	1.00 (Referent)	155 (34.3)	89 (27.7)	1.00 (Referent)	398 (36.5)	291 (33.9)	1.00 (Referent)
Ever	1.21 (0.99-1.47, p=0.060)	297 (65.7)	232 (72.3)	1.34 (0.97-1.86, p=0.082)	574 (52.7)	518 (60.3)	1.29 (1.05-1.58, p=0.016)
Missing	-	-	-	-	118 (10.8)	50 (5.8)	0.48 (0.30-0.76, p=0.002)
Aspirin/NSAID use							
Never	1.00 (Referent)	208 (46.0)	129 (40.2)	1.00 (Referent)	235 (21.6)	159 (18.5)	1.00 (Referent)
Ever	1.36 (1.04-1.77, p=0.023)	244 (54.0)	192 (59.8)	1.45 (1.08-2.00, p=0.015)	277 (25.4)	235 (27.4)	1.40 (1.06-1.85, p=0.017)
Missing	-	-	-	-	578 (53.0)	465 (54.1)	1.39 (1.07-1.81, p=0.014)
Heartburn symptoms status							
Absent	1.00 (Referent)	70 (15.5)	73 (22.7)	1.00 (Referent)	145 (13.3)	159 (18.5)	1.00 (Referent)
Present	0.62 (0.47-0.81, p=0.001)	382 (84.5)	248 (77.3)	0.56 (0.38-0.83, p=0.004)	684 (62.8)	524 (61.0)	0.69 (0.53-0.89, p=0.005)
Missing	-	-	-	-	261 (23.9)	176 (20.5)	0.79 (0.55-1.12, p=0.182)
T stage							
I	1.00 (Referent)	132 (29.2)	44 (13.7)	1.00 (Referent)	232 (21.3)	80 (9.3)	1.00 (Referent)
II	2.40 (1.78-3.25, p<0.001)	110 (24.3)	85 (26.5)	2.33 (1.48-3.69, p<0.001)	245 (22.5)	197 (22.9)	2.31 (1.68-3.20, p<0.001)
III	2.92 (2.22-3.84, p<0.001)	200 (44.2)	186 (57.9)	2.68 (1.80-4.06, p<0.001)	459 (42.1)	440 (51.2)	2.61 (1.96-3.50, p<0.001)
IV	3.16 (1.73-5.78, p<0.001)	10 (2.2)	6 (1.9)	1.92 (0.60-5.69, p=0.250)	25 (2.3)	26 (3.0)	2.84 (1.53-5.28, p=0.001)
Missing	-	-	-	-	129 (11.8)	116 (13.5)	2.63 (1.83-3.80, p<0.001)

^aadjusted for all covariates.

Table S3. Association of baseline characteristics with risk of BE+ve EAC phenotype compared to BE(?) EAC cases.

Characteristic	BE(?) EAC n (%)	BE+ve EAC n (%)	Univariable model OR (95% CI, p)	Minimally adjusted model ^a OR (95% CI, p)	Fully adjusted model ^b OR (95% CI, p)	Fully adjusted model excluding heartburn OR (95% CI, p)
Age group at diagnosis						
< 50	75 (7.6)	67 (5.4)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
50 - 59	213 (21.6)	193 (15.6)	1.01 (0.69-1.49, p=0.942)	0.99 (0.68-1.46, p=0.965)	0.98 (0.66-1.46, p=0.929)	0.99 (0.67-1.47, p=0.969)
60 - 69	333 (33.8)	497 (40.2)	1.67 (1.17-2.39, p=0.005)	1.63 (1.14-2.33, p=0.008)	1.64 (1.13-2.38, p=0.009)	1.64 (1.14-2.38, p=0.008)
70+	364 (37.0)	478 (38.7)	1.47 (1.03-2.10, p=0.034)	1.44 (1.01-2.06, p=0.045)	1.46 (1.01-2.11, p=0.047)	1.45 (1.00-2.10, p=0.049)
Sex						
Female	161 (16.3)	163 (13.2)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Male	824 (83.7)	1072 (86.8)	1.29 (1.01-1.63, p=0.037)	1.25 (0.99-1.59, p=0.063)	1.32 (1.03-1.70, p=0.026)	1.30 (1.02-1.67, p=0.036)
BMI group at baseline						
Normal	248 (25.2)	268 (21.7)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Overweight	307 (31.2)	422 (34.2)	1.27 (1.01-1.60, p=0.038)	1.25 (1.00-1.58, p=0.052)	1.14 (0.90-1.44, p=0.282)	1.16 (0.91-1.46, p=0.227)
Obese	195 (19.8)	304 (24.6)	1.44 (1.12-1.85, p=0.004)	1.49 (1.16-1.92, p=0.002)	1.34 (1.03-1.74, p=0.028)	1.36 (1.05-1.76, p=0.021)
Missing	235 (23.9)	241 (19.5)	0.95 (0.74-1.22, p=0.681)	0.96 (0.75-1.24, p=0.763)	0.90 (0.66-1.24, p=0.522)	0.89 (0.65-1.22, p=0.469)
Cigarette smoking status						
Never	304 (30.9)	452 (36.6)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Ever	562 (57.1)	665 (53.8)	0.80 (0.66-0.96, p=0.015)	0.79 (0.65-0.95, p=0.011)	0.78 (0.64-0.95, p=0.014)	0.79 (0.65-0.96, p=0.019)
Missing	119 (12.1)	118 (9.6)	0.67 (0.50-0.89, p=0.007)	0.67 (0.50-0.90, p=0.007)	0.88 (0.59-1.32, p=0.531)	0.82 (0.57-1.20, p=0.310)
Aspirin/NSAID use						
Never	201 (20.4)	257 (20.8)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Ever	263 (26.7)	328 (26.6)	0.98 (0.76-1.25, p=0.842)	0.94 (0.73-1.20, p=0.613)	0.92 (0.71-1.19, p=0.521)	0.94 (0.73-1.21, p=0.635)
Missing	521 (52.9)	650 (52.6)	0.98 (0.78-1.21, p=0.825)	0.96 (0.77-1.20, p=0.716)	1.03 (0.80-1.31, p=0.835)	1.00 (0.79-1.27, p=0.976)
Heartburn symptoms status						
Absent	144 (14.6)	150 (12.1)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	-
Present	599 (60.8)	818 (66.2)	1.31 (1.02-1.69, p=0.035)	1.34 (1.04-1.72, p=0.025)	1.29 (0.99-1.67, p=0.060)	-
Missing	242 (24.6)	267 (21.6)	1.06 (0.79-1.41, p=0.695)	1.07 (0.80-1.43, p=0.644)	1.08 (0.76-1.54, p=0.670)	-
T stage						
I	116 (11.8)	294 (23.8)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
II	192 (19.5)	279 (22.6)	0.57 (0.43-0.76, p<0.001)	0.56 (0.42-0.75, p<0.001)	0.57 (0.43-0.76, p<0.001)	0.58 (0.43-0.77, p<0.001)
III	424 (43.0)	481 (38.9)	0.45 (0.35-0.57, p<0.001)	0.45 (0.35-0.58, p<0.001)	0.48 (0.37-0.62, p<0.001)	0.47 (0.37-0.61, p<0.001)
IV	18 (1.8)	26 (2.1)	0.57 (0.30-1.09, p=0.084)	0.57 (0.30-1.09, p=0.083)	0.58 (0.31-1.12, p=0.101)	0.57 (0.30-1.10, p=0.090)
Missing	235 (23.9)	155 (12.6)	0.26 (0.19-0.35, p<0.001)	0.26 (0.19-0.34, p<0.001)	0.27 (0.20-0.36, p<0.001)	0.26 (0.20-0.36, p<0.001)

^aadjusted for age group at diagnosis and gender.

^badjusted for all covariates.

Table S4. Associations of baseline characteristics with risk of BE-ve EAC phenotype compared to BE(?) EAC cases.

Characteristic	BE(?) EAC n (%)	BE-ve EAC n (%)	Univariable model OR (95% CI, p)	Minimally adjusted model ^a OR (95% CI, p)	Fully adjusted model ^b OR (95% CI, p)	Fully adjusted model excluding heartburn OR (95% CI, p)
Age group at diagnosis						
< 50	75 (7.6)	59 (6.7)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
50 - 59	213 (21.6)	184 (20.9)	1.10 (0.74-1.63, p=0.642)	1.11 (0.75-1.65, p=0.612)	1.15 (0.77-1.73, p=0.494)	1.14 (0.76-1.71, p=0.529)
60 - 69	333 (33.8)	317 (36.0)	1.21 (0.83-1.76, p=0.318)	1.22 (0.84-1.78, p=0.295)	1.24 (0.84-1.82, p=0.279)	1.23 (0.84-1.81, p=0.296)
70+	364 (37.0)	320 (36.4)	1.12 (0.77-1.63, p=0.559)	1.13 (0.78-1.64, p=0.530)	1.14 (0.78-1.68, p=0.497)	1.14 (0.78-1.67, p=0.507)
Sex						
Female	161 (16.3)	158 (18.0)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Male	824 (83.7)	722 (82.0)	0.89 (0.70-1.14, p=0.357)	0.89 (0.70-1.13, p=0.332)	0.87 (0.68-1.12, p=0.277)	0.88 (0.69-1.13, p=0.322)
BMI group at baseline						
Normal	248 (25.2)	255 (29.0)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Overweight	307 (31.2)	317 (36.0)	1.00 (0.79-1.27, p=0.972)	1.01 (0.80-1.28, p=0.928)	1.00 (0.79-1.27, p=0.995)	1.00 (0.78-1.27, p=0.970)
Obese	195 (19.8)	155 (17.6)	0.77 (0.59-1.02, p=0.066)	0.78 (0.59-1.03, p=0.075)	0.79 (0.60-1.05, p=0.101)	0.79 (0.60-1.04, p=0.098)
Missing	235 (23.9)	153 (17.4)	0.63 (0.48-0.83, p=0.001)	0.63 (0.48-0.83, p=0.001)	0.78 (0.56-1.09, p=0.143)	0.79 (0.57-1.09, p=0.153)
Cigarette smoking status						
Never	304 (30.9)	298 (33.9)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Ever	562 (57.1)	532 (60.5)	0.97 (0.79-1.18, p=0.731)	0.97 (0.79-1.18, p=0.739)	0.98 (0.79-1.21, p=0.839)	0.97 (0.79-1.20, p=0.790)
Missing	119 (12.1)	50 (5.7)	0.43 (0.30-0.62, p<0.001)	0.43 (0.29-0.61, p<0.001)	0.44 (0.27-0.69, p=0.001)	0.43 (0.28-0.66, p<0.001)
Aspirin/NSAID use						
Never	201 (20.4)	161 (18.3)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
Ever	263 (26.7)	243 (27.6)	1.15 (0.88-1.51, p=0.301)	1.15 (0.88-1.51, p=0.307)	1.18 (0.89-1.56, p=0.247)	1.14 (0.86-1.50, p=0.354)
Missing	521 (52.9)	476 (54.1)	1.14 (0.90-1.45, p=0.286)	1.13 (0.89-1.45, p=0.309)	1.33 (1.02-1.74, p=0.036)	1.31 (1.02-1.70, p=0.037)
Heartburn symptoms status						
Absent	144 (14.6)	160 (18.2)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	-
Present	599 (60.8)	543 (61.7)	0.82 (0.63-1.05, p=0.115)	0.81 (0.63-1.04, p=0.101)	0.80 (0.61-1.03, p=0.085)	-
Missing	242 (24.6)	177 (20.1)	0.66 (0.49-0.89, p=0.006)	0.65 (0.48-0.88, p=0.005)	0.83 (0.58-1.19, p=0.322)	-
T stage						
I	116 (11.8)	87 (9.9)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
II	192 (19.5)	200 (22.7)	1.39 (0.99-1.96, p=0.059)	1.40 (0.99-1.97, p=0.056)	1.39 (0.98-1.96, p=0.065)	1.37 (0.97-1.95, p=0.071)
III	424 (43.0)	447 (50.8)	1.41 (1.03-1.92, p=0.030)	1.42 (1.04-1.94, p=0.026)	1.42 (1.03-1.94, p=0.030)	1.41 (1.03-1.94, p=0.031)
IV	18 (1.8)	26 (3.0)	1.93 (1.00-3.78, p=0.052)	1.95 (1.01-3.84, p=0.048)	1.94 (1.00-3.86, p=0.054)	1.94 (1.00-3.85, p=0.054)
Missing	235 (23.9)	120 (13.6)	0.68 (0.48-0.97, p=0.034)	0.69 (0.48-0.98, p=0.038)	0.67 (0.47-0.96, p=0.029)	0.67 (0.47-0.96, p=0.027)

^aadjusted for age group at diagnosis and gender.^badjusted for all covariates.

Table S5. Baseline demographics of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) patients

	BE (n=256)	BE+ve EAC (n=252)	BE-ve EAC (n=183)
Age at diagnosis; years			
Mean [SD]	67.9 [11.0]	67.2 [9.2]	65.6 [9.5]
Median [Q1, Q3]	68.8 [61.0, 76.0]	67.7 [61.4, 74.5]	66.9 [59.3, 72.7]
Age group at diagnosis, n (%)			
< 50 years old	16 (6.7)	10 (4.0)	10 (5.5)
50 - 59 years old	35 (14.5)	44 (17.5)	39 (21.3)
60 - 69 years old	81 (33.4)	94 (37.3)	69 (37.7)
70+ years old	110 (45.5)	104 (41.3)	65 (35.5)
Missing	14 (5.5)	0 (0)	0 (0)
Sex, n (%)			
Female	35 (14.6)	33 (13.1)	27 (14.8)
Male	205 (85.4)	219 (86.9)	156 (85.2)
Missing	16 (6.25)	0 (0)	0 (0)
Cigarette smoking status, n (%)			
Never	69 (35.0)	88 (36.8)	60 (33.9)
Ever	131 (66.8)	151 (63.2)	117 (66.1)
Missing	60 (23.4)	13 (5.2)	6 (3.3)
BMI group at diagnosis, n (%)			
Underweight	1 (0.50)	0 (0)	2 (1.27)
Normal	44 (12.0)	59 (28.6)	47 (29.7)
Overweight	84 (42.0)	77 (37.4)	70 (44.3)
Obese	71 (35.5)	70 (34.0)	39 (24.7)
Missing	56 (21.9)	46 (18.3)	25 (13.7)
Heartburn symptoms status, n (%)			
Absent	15 (7.0)	35 (17.2)	34 (24.1)
Present	199 (93.0)	169 (82.8)	107 (75.9)
Missing	42 (16.4)	48 (19.0)	42 (23.0)

Table S6. Baseline characteristics of the esophageal adenocarcinoma (EAC) cases with whole-genome sequencing, overall and according to phenotype.

Characteristic	BE+ve OAC (n=252)	BE-ve OAC (n=183)	BE(?) OAC (n=275)	Overall (n=710)
Age at diagnosis; years				
Mean [SD]	67.2 [9.2]	65.6 [9.5]	67.4 [10.0]	66.9 [9.6]
Median [Q1, Q3]	67.7 [61.4, 74.5]	66.9 [59.3, 72.7]	68.0 [60.4, 75.4]	67.6 [60.4, 74.0]
Age group at diagnosis, n (%)				
< 50 years old	10 (4.0)	10 (5.5)	14 (5.1)	34 (4.8)
50 - 59 years old	44 (17.5)	39 (21.3)	53 (19.3)	136 (19.2)
60 - 69 years old	94 (37.3)	69 (37.7)	86 (31.3)	249 (35.1)
70+ years old	104 (41.3)	65 (35.5)	122 (44.3)	288 (40.6)
Sex, n (%)				
Female	33 (13.1)	27 (14.8)	47 (17.1)	107 (15.0)
Male	219 (86.9)	156 (85.2)	228 (82.9)	603 (84.9)
Ethnicity, n (%)				
White	241 (95.6)	175 (95.6)	266 (96.7)	682 (96.1)
Other	0 (0)	1 (0.5)	2 (0.7)	3 (0.4)
Missing	11 (4.4)	7 (3.8)	7 (2.5)	25 (3.5)
BMI group at diagnosis, n (%)				
Underweight	0 (0)	2 (1.1)	10 (3.6)	12 (1.7)
Normal	59 (23.4)	47 (25.7)	59 (21.5)	165 (23.2)
Overweight	77 (30.6)	70 (38.3)	81 (29.5)	228 (32.1)
Obese	70 (27.8)	39 (21.3)	55 (20.0)	164 (23.1)
Missing	46 (18.3)	25 (13.7)	70 (25.5)	141 (19.9)
Cigarette smoking status, n (%)				
Never	88 (34.9)	60 (32.8)	86 (31.3)	234 (33.0)
Ever	151 (59.9)	117 (63.9)	169 (61.5)	437 (61.5)
Missing	13 (5.2)	6 (3.3)	20 (7.3)	39 (5.5)
Aspirin/NSAID use, n (%)				
Never	56 (22.2)	38 (20.8)	46 (16.7)	140 (19.7)
Ever	76 (30.2)	47 (25.7)	59 (21.5)	182 (25.6)
Missing	120 (47.6)	98 (53.6)	170 (61.8)	388 (54.6)
Heartburn symptoms status, n (%)				
Absent	35 (13.9)	34 (18.6)	47 (17.1)	116 (16.3)
Present	169 (67.1)	107 (58.5)	159 (57.8)	435 (61.3)
Missing	48 (19.0)	42 (23.0)	69 (25.1)	159 (22.4)
Total alcohol intake/week; units				
Mean [SD]	22.8 [32.6]	22.1 [17.1]	29.2 [51.4]	24.7 [36.7]
Median [Q1, Q3]	15.0 [4.75, 22.5]	20.0 [9.00, 28.0]	18.0 [6.00, 35.0]	18.0 [7.00, 30.0]
Missing	200 (79.4)	138 (75.4)	226 (82.2)	564 (79.4)
TNM, n (%)				
I	62 (24.6)	21 (11.5)	12 (4.4)	95 (13.4)
II	54 (21.4)	31 (16.9)	23 (8.4)	108 (15.2)
III	98 (38.9)	97 (53.0)	66 (24.0)	261 (36.8)
IV	4 (1.6)	10 (5.5)	1 (0.4)	15 (2.1)
Missing	34 (13.5)	24 (13.1)	173 (62.9)	231 (32.5)